Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)

Ying Liao; Changhua Zhu; Xiaoxia Song; Jiugen Ruan; Yao Ding; Yuan Chen; Qiujuan Yang

doi:10.12659/MSM.934493

24 March 2022: Clinical Research

Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)

Ying Liao ^1BCE , Changhua Zhu ^2A* , Xiaoxia Song ^1CF , Jiugen Ruan ^2BCDF , Yao Ding ^2CF , Yuan Chen ^3BCDEF , Qiujuan Yang ^1F

DOI: 10.12659/MSM.934493

Med Sci Monit 2022; 28:e934493

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 5 The dMMR proteins in endometrial cancer tissue samples were stained for immunohistochemistry. The figure was created using Adobe Illustrator CC 2019, Adobe Systems Incorporated.

Back to the Article

Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)

Your Privacy